June 7, 2019
Nippon Boehringer Ingelheim President Yoshiaki Aono After suffering a near-20% dip in its drug sales in 2018, Nippon Boehringer Ingelheim has been showing a sign of a turnaround since the latter half of the year with strong revenues delivered from...read more